Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 502 participants.

Also called NCT04661709

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 502 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04661709
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04661709. Randomized; triple masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2023-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris
Condition
Coronary Heart Disease
Condition
Unstable Angina
Condition
Chinese Herbal Medicine
Intervention (Drug)
Wen Xin granule
Intervention (Drug)
Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Intervention (Drug)
Atorvastatin Calcium
Intervention (Drug)
Isosorbide Mononitrate Tab 20 MG
Intervention (Drug)
Metoprolol Tartrate Tab 25 MG
Intervention (Drug)
Aspirin Enteric-coated Tablets
Intervention (Drug)
WXG placebo
Intervention (Drug)
Trimetazidine Dihydrochloride Tablets
Intervention (Drug)
glyceryl trinitrate
Lead sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences (class: other)
Collaborator
Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine (class: not stated)
Collaborator
National Natural Science Foundation of China (class: other government)

Record details

Record id
cardio:ct-nct04661709
Content hash
e96133f7c1d484be78217d1b3a989264f80c277a2f8d2b9eddaf2bd7dd5dcc7f